<div id="readability-page-1"><p>Shares of Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) have been assigned an average recommendation of &#34;Hold&#34; from the fourteen analysts that are currently  covering the stock, MarketBeat reports. One analyst  has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to  the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $76.9231.</p><p>HSIC has been the topic of a number of analyst reports. Barrington Research  set a $79.00 price target on Henry Schein and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, November 5th. Wells Fargo &amp; Company upped their target price on shares of Henry Schein from $70.00 to $76.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, November 5th. Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an &#34;overweight&#34; rating and a $86.00 price target for the company. JPMorgan Chase &amp; Co. boosted their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, November 5th. Finally, Evercore ISI raised their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, November 5th.</p><p><b>Read Our Latest Stock Report on Henry Schein</b></p><h2>Institutional Trading of Henry Schein</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. raised its holdings in shares of  Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company's stock valued at $165,594,000 after buying an additional 2,199,695 shares during the last quarter.  Norges Bank purchased a new position in shares of  Henry Schein during the second quarter worth about $89,476,000.  M.D. Sass LLC acquired a new position in  Henry Schein in the 2nd quarter valued at about $79,201,000.  Schroder Investment Management Group raised its stake in  Henry Schein by 149.3% during the 2nd quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company's stock valued at $114,243,000 after acquiring an additional 936,471 shares during the last quarter.  Finally, Bank of America Corp DE lifted its position in  Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company's stock worth $72,712,000 after acquiring an additional 668,182 shares during the period. Institutional investors and hedge funds own  96.62% of the company's stock. </p><h2>Henry Schein Stock Performance</h2><p>Shares of HSIC stock opened at $76.13 on Friday. The firm has a 50 day moving average of $71.79 and a two-hundred day moving average of $69.98. The stock has a market capitalization of $8.96 billion, a PE ratio of 24.09, a P/E/G ratio of 2.34 and a beta of 0.89. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. Henry Schein has a 52 week low of $60.56 and a 52 week high of $82.49. </p><p>Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to analysts' expectations of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS.  On average, research analysts predict that  Henry Schein will post 4.74 EPS for the current fiscal year. </p><h2>Henry Schein Company Profile</h2> (Get Free Report)<p>Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.  </p><p>In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.</p><h2>Read More</h2><ul><li>Five stocks we like better than Henry Schein</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFNJQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SFNJQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Henry Schein Right Now?</h2><p>Before you consider Henry Schein, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.</p><p>While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HSIC

<p>Henry Schein, Inc. (NASDAQ:HSIC) has received an average "Hold" recommendation from 14 analysts. The stock has varied ratings: one "sell," seven "hold," and six "buy." The average price target is $76.92. Recent analyst reports include Barrington Research's $79 target and "outperform" rating, Wells Fargo's $76 target and "equal weight" rating, and Barclays' $86 target and "overweight" rating. Institutional investors have significantly increased their holdings in the company.</p>

Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of "Hold" from Analysts